Supernus Pharmaceuticals (SUPN) stock had its Relative Strength (RS) Rating upgraded from 77 to 86 Thursday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of at least 80 as they launch their biggest price moves.
Supernus Pharmaceuticals stock is within a buy zone after moving past a 40.28 entry in a cup without handle. The proper buying range extends to 5% above the initial entry. Once a stock moves above that range, it's best to wait for it to set up another buying opportunity.
Earnings growth increased last quarter from 0% to 11%. But sales fell from 4% to -2%.
Supernus Pharmaceuticals stock holds the No. 53 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals (AUPH), Rigel Pharmaceuticals (RIGL) and Incyte (INCY) are among the top 5 highly rated stocks within the group. For industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
YOU MAY ALSO LIKE:
MarketSurge's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。